Introduction. Hypertensive disorders of pregnancy have been the most frequent cause of maternal death in Norway since 1996 and are strongly associated with substandard care. In the UK, the number of maternal deaths due to hypertensive disorders has decreased drastically due to the implementation of updated guidelines, indicating a potential for reducing the number of deaths in other countries as well. Through audits of maternal deaths, we aim to prevent future deaths from hypertensive disorders in pregnancy by identifying suboptimal factors in treatment. Material and methods. Maternal deaths in Norway from 1996 to 2014 were identified through linked registries. The Norwegian Maternal Mortality Audit Group performed all case assessments included in this study, classified the cause of death, evaluated the treatment, and identified suboptimal factors to care in each case. Emphasis was placed on antihypertensive treatment, timing of delivery, stabilization before delivery, and quality of care. Learning points were prepared to improve the treatment of hypertensive disorders of pregnancy. Results. We identified 74 maternal deaths. The maternal mortality rate was 6.5 deaths per 100 000 live births. The most common cause of death was hypertensive disorders (n = 16 deaths). In 14 of these deaths (87%), the audit group concluded that improvements to care could have made a difference to the outcome. Conclusions. In 1996-2014, hypertensive disorders were the most common cause of maternal death in Norway. Our study indicates that such deaths can be prevented by improvements in antihypertensive treatment and the timing of delivery.
Introduction
Hypertensive disorders of pregnancy are a leading cause of death during pregnancy and delivery globally, with an estimated 40 000 women dying each year from this condition (1) . In Norway, hypertensive disorders have been reported to be the leading cause of maternal death during the time periods 1976-1995 and 1996-2011 (2,3) , and the leading cause of maternal death in the Netherlands between 1993 and 2005 (4).
During 2009-2011, the maternal mortality ratio (MMR) from hypertensive disorders in Norway was 1.2 per 100 000 live births (2, 5) . In comparison, hypertensive disorders ranked fourth as a direct cause of maternal deaths in the UK during 2009-2012, with an MMR of 0.25 (6) . A further reduction of the MMR to 0.08 was reported in 2012-2014, during which only two women died from preeclampsia and eclampsia, which is approximately one death per 1 000 000 pregnancies (7) .
Deaths from hypertensive disorders have been associated with substandard care (8) (9) (10) , suggesting these deaths are avoidable. The remarkable reduction reported in the UK indicates considerable potential for reducing deaths in countries such as Norway, where hypertensive disorders are still one of the leading causes of maternal death. During the study period, the Norwegian obstetric guidelines gave no specific recommendations on the timing of delivery in women with hypertensive disorders, and antihypertensive treatment goals focused on thresholds for diastolic blood pressure. This may have contributed to a higher death rate, as the induction of labor beyond 37 weeks' gestation is associated with improved maternal outcome (11) , and systolic hypertension precedes intracranial hemorrhage in patients with preeclampsia (12) . Furthermore, no management protocol was recommended for fluid restriction. Unrestricted fluid administration is a significant risk factor for the development of acute pulmonary edema (13, 14) . Thus, audits to define elements of substandard care in each case are needed to reduce maternal deaths due to hypertensive disorders in Norway.
The aim of the current study was to assess maternal deaths from hypertensive disorders of pregnancy. In particular, we wanted to identify elements of substandard care for which improvements might have made a difference in the outcome, including antihypertensive treatment, anticonvulsant treatment and prophylaxis, and timing of delivery.
Material and methods
According to the 10th revision of the International Classification of Disease (ICD-10), a maternal death is the death of a woman while pregnant or within 42 days of the termination of pregnancy from any cause related to or aggravated by the pregnancy or its management, but not from accidental or incidental causes. We calculated the MMR as the number of maternal deaths per 100 000 live births (15) . The denominator data were collected from the Medical Birth Registry of Norway (MBRN). The MBRN contains information on women who gave birth at or after gestational week 22 or to an infant weighing ≥500 g.
We identified cases of maternal death in 1996-2014 using the MBRN and the Norwegian Cause of Death Registry. From 2009, we also linked the two registries with the Inpatient Registry, which has been in operation in Norway since 2009. In addition, some deaths were reported directly to the audit group by the hospitals. All permanent and non-permanent residents were included. However, we were not able to identify any possible maternal deaths that may have occurred among undocumented immigrants.
In 2010, the Norwegian Maternal Mortality Audit Group consisting of nine obstetricians was established. Specialists in anesthesiology, pathology and cardiology were consulted when needed. The audit group conducted a structured audit of all maternal deaths that occurred during the study period. Deaths caused by hypertensive disorders were included in this study. By scrutinizing medical records and autopsy reports, the underlying cause of death was classified, the treatment evaluated and any possible suboptimal elements of care (organizational, medical or maternal/social factors) identified in each case. The medical records were anonymized before the audits were performed. Each case audit started with an independent analysis by two group members, followed by a discussion in the entire audit group. The cause of death and quality of care were classified using a modified Confidential Enquiry into Maternal and Child Health (CEMACH) form, maintained by the Maternal, Newborn and Infant Clinical Outcome Review Program (MBRRACE-UK) (7) . The group then proceeded with an in-depth analysis of management, treatment delays and quality of care in each case of death. The following key issues were emphasized: antihypertensive treatment, timing of delivery and stabilization of the patient before delivery. The quality of care was categorized as good care, improvements to care that would have made no difference to the outcome, and improvements to care that might have made a difference to the outcome. Current clinical care guidelines constituted the reference standard. Finally, the group agreed on key messages on potential improvements to future medical care in each case and the relevant compound group.
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Results
During 1996-2014, a total of 1 127 946 live births and 74 maternal deaths were reported to the MBRN. The overall MMR was 6.5 per 100 000 live births. The causes of death are shown in Figure 1 . The main underlying cause of death was hypertensive disorders of pregnancy (n = 16), followed by cardiovascular diseases (n = 11), thromboembolism (n = 10) and amniotic fluid embolism (n = 8). The MMR due to hypertensive disorders of pregnancy was 1.3 per 100 000 live births.
All 16 women who died from hypertensive disorders were diagnosed with preeclampsia (n = 9), eclampsia (n = 4), or HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome (n = 3). The characteristics of women who died from hypertensive disorders and other causes are provided in Table 1 . Compared with women who died from other causes (n = 58), women who died from hypertensive disorders were more often primiparas (75 vs. 26%), delivered by emergency cesarean section (75 vs. 50%) and tended to be younger (29.7 years, range 20-41 vs. 31.5 years, range 19-43 years). In addition, among the 16 women who died from hypertensive disorders, five were obese (body mass index ≥30) and three were not of Norwegian origin. None had severe chronic diseases predisposing them to preeclampsia in the index pregnancy. One woman was diagnosed with mild, chronic hypertension. Of four parous women, two had preeclampsia in a previous pregnancy and one, previous gestational diabetes. Table 2 gives a brief summary of all 16 cases, including the cause of death, autopsy results, treatment delay and quality of care. Seven deaths were associated with pulmonary edema, six with intracranial hemorrhage, two with hepatic failure, and one was unknown. Failure of effective antihypertensive treatment was the most common element of substandard care in the women who died from hypertensive disorders during the study period. Fourteen women did not receive adequate antihypertensive treatment, eight women received no antihypertensive treatment at all, and in six women the treatment was insufficient to reduce their blood pressure adequately.
Eleven women had a reported systolic blood pressure of 180-220 mmHg, but no antihypertensive medication or only labetalol (100 mg orally) was administered. Four of the six women who died from an intracranial hemorrhage were reported to have a systolic blood pressure ≥200 mmHg without the initiation of any adequate antihypertensive treatment.
Pulmonary edema was as common as intracranial hemorrhage. Pulmonary edema may occur secondary to critically elevated blood pressure or from unrestricted fluid administration. A lack of restrictive fluid management, especially with cesarean deliveries, may have contributed in these cases.
Inadequate monitoring of blood pressure after admission was also common. In one case (case 4, Table 2 ), blood pressure measurements were not made between the woman's last antenatal visit one week before the onset of labor and her sudden collapse four hours after delivery of the infant. She was admitted in gestational week 39 due to contractions and had a normal vaginal delivery shortly thereafter. HELLP syndrome was diagnosed postpartum with low platelets and elevated liver enzymes. A CT scan showed intracranial hemorrhage, and she died 17 days later. Another woman (case 14, Table 2 ) was induced in gestational week 39 due to preeclampsia. Her blood pressure was reported to be 168/93 mmHg in the evening of the induction, but no antihypertensive treatment was initiated and her blood pressure was not monitored during the night. She was found dead in the hospital the next morning. Furthermore, five women with severe symptoms of preeclampsia delivered by emergency cesarean without proper stabilization before surgery. One woman (case 7, Table 2 ) was referred to the hospital in gestational week 33 due to suspected preeclampsia. At the hospital, a blood pressure of 160/90 mmHg and proteinuria +3 were reported. She was sent home without any treatment and returned for her check-up one week later with a blood pressure of 190/130 mmHg. Only labetalol (100 mg orally) was administered. She delivered by an emergency cesarean shortly thereafter due to fetal distress without necessary stabilization, had a seizure in the operating room, and died.
Delay of delivery was another common event of substandard care. In seven cases, labor was induced too late to save the mother. One woman (case 5, Table 2 ) was followed from gestational week 34 due to preeclampsia. She was partly admitted for observation and partly followed as an outpatient. Labor was not induced until gestational week 38 even though her condition gradually deteriorated with increasing blood pressure and proteinuria. At the time of induction, her blood pressure was 190/ 120 mmHg and urinary protein:creatinine ratio >300 mg/ mmol. She was delivered by emergency cesarean due to sudden collapse and died in the operating room. Another woman (case 6, Table 2 ) was admitted in gestational week 37 due to preeclampsia with a blood pressure of 200/100 mmHg. She was admitted for observation but antihypertensive treatment was not started. After two days, labor was induced because her blood pressure remained high (180/100 mmHg), but an emergency cesarean was performed shortly afterwards due to fetal distress. After delivery, the woman received 200 mg labetalol orally due to headache and elevated blood pressure (200/ 120 mmHg) but she died two hours later due to an intracranial hemorrhage. A third woman (case 15, Table 2 ) with a twin pregnancy developed symptoms of severe preeclampsia in gestational week 32 and HELLP syndrome was diagnosed at admission. Delivery was delayed for a course of corticosteroids to affect lung maturation before delivery. However, the woman's clinical condition deteriorated and the baby was delivered by emergency cesarean 12 h later. The mother died of multiorgan failure shortly after surgery.
The Norwegian Maternal Mortality Audit Group has provided several learning points based on the audit material in order to improve the future care of pregnant women who develop hypertensive disorders (Table 3) . These learning points are not a complete guideline on the management of hypertensive diseases in pregnancy but are based on elements of substandard care identified in cases of maternal death. In 14 of the 16 women (87%) who died from hypertensive disorders, the audit group concluded that improvements in care could have changed the outcome.
Discussion
In this study, we found that hypertensive disorders of pregnancy were the most frequent underlying cause of maternal deaths in Norway during 1996-2014. We identified evidence of substandard care in which improvements could have made a difference to the outcome in 87% of the women who died due to hypertensive disorders. This finding is in line with a Dutch study on maternal deaths during 1993-2002 (4) in which 90% of the women who died from hypertensive disorders of pregnancy received substandard care.
To be able to advise on targeted measures towards preventing maternal deaths, we need accurate data on the number of maternal deaths and the causes. Maternal deaths in Norway have been found to be underreported by 54% in official statistics (5), indicating that half of the deaths included in our study may not have appeared in official statistics. Other countries have also reported substantial underreporting of maternal deaths (16, 17) . To achieve better identification in this study, we used multiple sources: extensive registry linkages, direct reporting of maternal deaths from the hospitals to the audit group, and hospital records and autopsy data. We think we managed to identify nearly all direct and indirect deaths. However, we may have missed cases in which the delivery was not reported to the MBRN and no obstetric diagnosis was reported to the Cause of Death Registry. Furthermore, unregistered deaths during early gestation, before the pregnancy was confirmed, may have occurred. Better identification of deaths in early pregnancy is required in the future. In addition, deaths by suicide related to a termination of pregnancy may have been missed. Termination of pregnancy is often not reported on the death certificates (18) . To determine whether the death was coincidental or maternal, we need to be able to assess to what degree the termination contributed to the decision to commit suicide and whether the suicide was related to other adverse life circumstances (19) .
The classification of maternal deaths is sometimes difficult. In a retrospective clinical audit study, the quality of the collected information is never optimal, as the audit is based on past clinical documentation. There is always a possibility of information bias due to the misclassification of exposures. Autopsies can help elucidate factors that contribute to death and pathology in different organ systems (20) . An autopsy was performed in 11 of the cases, with a clear cause of death in six cases. In Norway, we do not have specific guidelines on how to perform autopsies after maternal death. In several of the cases, the autopsy report did not help us classify the cause of death. To increase the quality of the audits, we should develop similar guidelines on autopsy practice as in the UK (21) to clearly determine what actually happened to cause each maternal death. Audit reports on maternal deaths are meant to serve as the basis for recommendations on how to improve obstetric practice; therefore, it is crucial that the quality of the audits is optimal.
The Norwegian Gynecological Association first published the National Guidelines in Obstetrics in 1995, with revisions in 1998, 2008 and 2014 (22) . The last revision was released after the study period ended. In the first version of the guidelines, antihypertensive treatment was advised when the blood pressure exceeded 160/ 110 mmHg. The treatment goal was a diastolic blood pressure of approximately 100 mmHg, with no specific advice on the treatment goal for the systolic blood pressure. This may partly explain why eight women in the study never received any antihypertensive treatment even though they were reported to have high systolic blood pressures. In the second revision in 2008, specific advice on reducing an elevated systolic blood pressure below 160 mmHg was added to avoid intracranial hemorrhage. The current recommendation from 2014 is to keep the systolic blood pressure below 150 mmHg and the diastolic blood pressure between 80 and 100 mmHg. Unrestricted fluid administration is a significant risk factor for the development of acute pulmonary edema but it may also occur secondary to critically elevated blood pressure (13) . To reduce the risk, a general approach of restricted fluid administration and close observation of the fluid balance are important. Ideally, more specific advice on restrictive intravenous fluid administration could be included in the Norwegian guidelines. Specific recommendations on the timing of delivery are lacking in the revisions. In 1998, the advice was to pay close attention and to continuously review the situation, but no specific advice on the timing of delivery was given. In the second version, delivery was emphasized as the only curative treatment, but without any specific recommendations on timing. Expectant management may have been preferred in many hospitals to avoid unnecessary induction of labor and to increase fetal benefits from a longer pregnancy duration. The benefits of immediate delivery must always be weighed against the consequences of a preterm delivery. However, hypertension is still a major cause of stillbirths worldwide (19) , and both the mother and infant run the risk of dying if delivery is delayed. The 2009 HYPITAT I study (11) revealed that a conservative approach to treatment and elective delivery leads to a significantly higher risk of maternal morbidity compared with an approach with induction before gestational week 37. By solely decreasing the blood pressure and not electively inducing labor, there is a risk of covering up a more serious disease with worse outcomes (23) . In 2012-2014, only two women died from preeclampsia and eclampsia in the UK, which is approximately one death per 1 000 000 pregnancies (7). Sheenan et al. (9) suggested that the introduction of national evidence-based guidelines focusing on the systematic use of interventions may be the catalyst that reduced deaths from hypertensive disorders of pregnancy in the UK. A similar reduction in maternal deaths from hypertensive disorders should also be within reach in other countries with a high death rate from hypertensive disorders. Evidence-based blood pressure treatment and reducing the time from start of symptoms to delivery seem to be major factors in achieving this goal. The efficacy of anticonvulsant therapies, such as magnesium sulfate, for the prevention of eclamptic fits and to reduce the risk of maternal death without any substantial harmful effects on the mother or child is well known (24) . We found that anticonvulsant treatment was rarely used in the women who died from hypertensive disorders during the study period.
In some cases, the decision to deliver by cesarean section seemed to be based solely on fetal indications, and further efforts to stabilize the mother with magnesium sulfate and antihypertensive treatment before surgery may have led to another outcome.
In several studies, the systematic use of evidence-based clinical guidelines in the management of preeclampsia has been reported to be a key factor in reducing maternal mortality from preeclampsia. Gibson et al. (25) reported an increased risk of developing hypertensive complications for each additional week the pregnancy was continued in low-risk women managed expectantly at term compared with elective inductions, with an associated increase in both maternal and neonatal morbidity. Elective induction of women with hypertensive disorders significantly lowered the rate of both cesarean delivery and maternal morbidity, as well as composite neonatal morbidity after 37 weeks, which is in line with the findings in the HYPITAT study (11) . Clark et al. (26) reported a dramatically reduced number of deaths due to preeclampsia after implementing disease-specific protocols with clear blood pressure thresholds and an emphasis on prompt recognition and management of preeclampsia. Similarly, Herrera et al. (27) were able to decrease the number of maternal deaths from preeclampsia by one-fifth by implementing guidelines for preventive care in high-risk preeclampsia patients.
In conclusion, hypertensive disorders were the most common cause of maternal death in Norway between 1996 and 2014. This study indicates that maternal deaths in Norway can be prevented by implementing evidencebased guidelines with a focus on the systematic use of interventions to treat hypertensive disorders in pregnancy.
